WO2025017210 - MONOGLYCERIDE LIPASE INHIBITORS IN THE TREATMENT OF PANCREATIC CANCER
National phase entry is expected:
Publication Number
WO/2025/017210
Publication Date
23.01.2025
International Application No.
PCT/EP2024/070672
International Filing Date
22.07.2024
Title **
[English]
MONOGLYCERIDE LIPASE INHIBITORS IN THE TREATMENT OF PANCREATIC CANCER
[French]
INHIBITEURS DE MONOGLYCÉRIDE LIPASE DANS LE TRAITEMENT DU CANCER DU PANCRÉAS
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
Inventors
BELOTSERKOVSKY, Jaroslav
DE LAAT, Vincent
SPOTBEEN, Xander
SWINNEN, Johannes
TALEBI, Ali
Priority Data
23186692.2
20.07.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1879 | |
| EPO | Filing, Examination, Granting | 8141 | |
| Japan | Filing, Examination, Granting | 1983 | |
| South Korea | Filing, Examination, Granting | 1687 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,430
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to compositions comprising an inhibitor of MGLL (Monoglyceride Lipase), and an immunotherapy agent for use in the treatment of pancreatic cancer.[French]
L'invention concerne des compositions comprenant un inhibiteur de MGLL (monoglycéride lipase), et un agent d'immunothérapie destiné à être utilisé dans le traitement du cancer du pancréas.